Japan· JP-4291091F2023
ラゼルチニブメシル酸塩水和物
A lazertinib product containing ラゼルチニブメシル酸塩水和物, registered in Japan by ヤンセンファーマ, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Lazertinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EB09 (lazertinib), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Lazertinib · ATC L01EB09
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lazertinib costs, country by country.
Normalised to the WHO defined daily dose (0.24 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lazertinib · price per daily dose (0.24 g)
USD · FX 28 Sept 2026
- CH Switzerland$339.05
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ラゼルチニブメシル酸塩水和物
- Manufacturer
- ヤンセンファーマ
- Country
- Japan (JP)
- ATC code
- L01EB09
- ATC class
- Lazertinib
- Defined daily dose
- 0.24 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L01EB09
Lazertinib, as other registers publish it.
- NorwayLazcluzeJanssen-Cilag Spa
- DenmarkLazcluzeJanssen-Cilag International NV
- PolandLazcluzeJanssen-Cilag International N.V.
- PolandLazcluzeJanssen-Cilag International N.V.
- IcelandLazcluzeJanssen-Cilag International NV*
- FinlandLazcluzeJanssen Cilag International
- FinlandLazcluzeJanssen Cilag International
- SwitzerlandLazcluze
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dddd66e4-7fd2-4454-a59f-43bf06921616 GET /v1/drugs/dddd66e4-7fd2-4454-a59f-43bf06921616?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２４０ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291091F2023",
"category": "内用薬",
"price_yen": 12354.7,
"generic_name": "ラゼルチニブメシル酸塩水和物",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about lazertinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.